Date: 2013-10-07
Type of information: Fundraising
Company: Defymed (France)
Investors: Centre Européen d\'Etude du Diabète (CEED) (France), Fonds Lorrain des Matériaux (France)
Amount: € 1.2 million
Funding type:
Planned used: These funds will be used to support the development of the bioartificial pancreas MAILPAN® (MAcroencapsulation of PANcreatic Islets).
Others: Defymed, a spin-off of the CeeD (Centre europeen d’etude du Diabete), has raised € 1.2 million from the french investment fund Fonds Lorrain des Matériaux and its historical shareholder, le Centre Européen d\'Etude du Diabète (CEED), with th support of Alsace BioValley and Semia incubator.
Defymed is also a member of the european BIOSID project that aims to understand the needs of insulin-secreting cells in the bioartificial pancreas and to validate the bioartificial pancreas MAILPAN® (MAcroencapsulation of PANcreatic Islets), associated with insulin-secreting cells, in large animals and then in humans. This prototype of bioartificial pancreas designed to treat type 1 diabetic patients was developed along different stages since 1996 and led to the creation of Defymed in 2011. The BIOSID project aims to bring the developed bioartificial pancreas MAILPAN® to the clinical stages of type 1 diabetic patients. From a clinical perspective, this device is a bioartificial pancreas that restores the physiological secretion of insulin necessary for the regulation of blood glucose. With the bioartificial pancreas, instead of being grafted as such, the transplanted insulin-producing cells are surrounded by an immunoprotective envelope.
Therapeutic area: Metabolic diseases
